A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland. Swiss Med Wkly [Internet]. 2025 Jan. 6 [cited 2025 Oct. 23];155(1):3777. Available from: https://www.smw.ch/index.php/smw/article/view/3777